Lung Cancer Therapeutics Market by Molecules, Disease, Cancer Type, Therapy, Distribution - Global Forecast 2025-2030- Product Image

Sale

Lung Cancer Therapeutics Market by Molecules, Disease, Cancer Type, Therapy, Distribution - Global Forecast 2025-2030

Report
193 Pages
October 2024
Region: Global
360iResearch™
ID: 4904951

UP TO €696EUR$697USD£578GBP OFF until Dec 31^st 2024

The Lung Cancer Therapeutics Market grew from USD 25.04 billion in 2023 to USD 27.12 billion in 2024. It is expected to continue growing at a CAGR of 8.39%, reaching USD 44.03 billion by 2030.

The lung cancer therapeutics market focuses on developing and commercializing treatments for lung cancer, which remains the leading cause of cancer-related deaths worldwide. The market encompasses pharmaceutical drugs, innovative therapies, and supportive care products designed to manage both small-cell and non-small-cell lung cancers. There is a compelling necessity for these therapeutics due to the high incidence and mortality rates associated with lung cancer, underscored by an aging global population, escalating pollution levels, and increased smoking prevalence. Applications primarily include chemotherapy, targeted therapy, immunotherapy, and radiation therapy, each serving distinctive roles in treatment protocols. End-users are mostly hospitals, cancer specialty clinics, and research institutes. Key growth factors include advancements in biomarker research, leading to more precise and effective treatments, alongside increasing approval of novel drugs and therapies by regulatory bodies. Potential opportunities lie in expanding personalized medicine approaches that tailor treatments to individual patient profiles, and the integration of artificial intelligence to enhance diagnostic accuracy and treatment outcomes. Recommendations for capitalizing on these opportunities involve investing in R&D, fostering collaborations with biotech firms for innovation, and focusing on emerging markets where unmet needs are significant. However, limitations persist, including high R&D costs, substantial regulatory hurdles, and the complexity of obtaining reimbursement approvals from healthcare payers. Additionally, the market faces challenges from generic competition, pricing pressures, and potential side effects of advanced therapies that impact adoption rates. Innovation areas ripe for exploration include next-generation sequencing for early detection, development of combination therapies to overcome drug resistance, and utilizing real-world data to refine treatment protocols. The market is highly dynamic, with an increasing emphasis on precision medicine and a shift towards outpatient care settings, necessitating continuous adaptation to thrive successfully.

Understanding Market Dynamics in the Lung Cancer Therapeutics Market

The Lung Cancer Therapeutics Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Increase in prevalence of lung cancer across the globe
- Growing awareness regarding enhanced health care
- Rising government initiatives for lung cancer treatment
Market Restraints
- Huge availability of the generic drugs
- Reduced life expectancy of patients undertaking lung cancer treatment
Market Opportunities
- Increasing funding in the field of research and development of new treatment
- Adoption of advanced therapy such as immunotherapy
Market Challenges
- Risk of side effects of radiation and chemotherapy

Exploring Porter’s Five Forces for the Lung Cancer Therapeutics Market

Porter’s Five Forces framework further strengthens the insights of the Lung Cancer Therapeutics Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Lung Cancer Therapeutics Market

External macro-environmental factors deeply influence the performance of the Lung Cancer Therapeutics Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Lung Cancer Therapeutics Market

The Lung Cancer Therapeutics Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Lung Cancer Therapeutics Market

The Lung Cancer Therapeutics Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Lung Cancer Therapeutics Market

The Lung Cancer Therapeutics Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lung Cancer Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Astellas Pharma Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Bristol Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, Genentech, Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis AG, Pfizer Inc., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Lung Cancer Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Molecules
- Biologics
- Small Molecules
Disease
- NSCLC
- SCLC
Cancer Type
- Lung Carcinoid Tumor
- Non-small Cell Lung Cancer
- Small Cell Lung Cancer
Therapy
- Chemotherapy
- Immunotherapy
  - Atezolizumab
  - Durvalumab
  - Nivolumab
  - Pembrolizumab
- Radiation Therapy
  - External Beam
  - Internal Beam
  - Systemic
- Targeted Therapy
  - Bevacizumab
  - Dabrafenib/Trametinib
  - Erlotinib Hydrochloride
  - Osimertinib
Distribution
- Hospital Pharmacies
- Online Phramacies
- Retail Pharmacies

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in prevalence of lung cancer across the globe
5.1.1.2. Growing awareness regarding enhanced health care
5.1.1.3. Rising government initiatives for lung cancer treatment
5.1.2. Restraints
5.1.2.1. Huge availability of the generic drugs
5.1.2.2. Reduced life expectancy of patients undertaking lung cancer treatment
5.1.3. Opportunities
5.1.3.1. Increasing funding in the field of research and development of new treatment
5.1.3.2. Adoption of advanced therapy such as immunotherapy
5.1.4. Challenges
5.1.4.1. Risk of side effects of radiation and chemotherapy
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Lung Cancer Therapeutics Market, by Molecules

6.1. Introduction
6.2. Biologics
6.3. Small Molecules

7. Lung Cancer Therapeutics Market, by Disease

7.1. Introduction
7.2. NSCLC
7.3. SCLC

8. Lung Cancer Therapeutics Market, by Cancer Type

8.1. Introduction
8.2. Lung Carcinoid Tumor
8.3. Non-small Cell Lung Cancer
8.4. Small Cell Lung Cancer

9. Lung Cancer Therapeutics Market, by Therapy

9.1. Introduction
9.2. Chemotherapy
9.3. Immunotherapy
9.3.1. Atezolizumab
9.3.2. Durvalumab
9.3.3. Nivolumab
9.3.4. Pembrolizumab
9.4. Radiation Therapy
9.4.1. External Beam
9.4.2. Internal Beam
9.4.3. Systemic
9.5. Targeted Therapy
9.5.1. Bevacizumab
9.5.2. Dabrafenib/Trametinib
9.5.3. Erlotinib Hydrochloride
9.5.4. Osimertinib

10. Lung Cancer Therapeutics Market, by Distribution

10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Phramacies
10.4. Retail Pharmacies

11. Americas Lung Cancer Therapeutics Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Lung Cancer Therapeutics Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Lung Cancer Therapeutics Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.4. Strategy Analysis & Recommendation

List of Figures

FIGURE 1. LUNG CANCER THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. LUNG CANCER THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2023 VS 2030 (%)
FIGURE 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
FIGURE 13. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
FIGURE 15. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. LUNG CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. LUNG CANCER THERAPEUTICS MARKET DYNAMICS
TABLE 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NSCLC, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SCLC, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LUNG CARCINOID TUMOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INTERNAL BEAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DABRAFENIB/TRAMETINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ERLOTINIB HYDROCHLORIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OSIMERTINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHRAMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 65. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 66. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 67. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 68. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 69. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 70. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 71. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 72. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 73. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 74. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 75. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 76. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 77. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 78. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 79. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 80. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 90. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 92. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 94. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 96. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 98. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 99. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 100. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 101. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 102. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 103. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 104. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 105. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 106. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 107. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 108. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 109. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 110. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 111. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 112. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 113. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 114. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 115. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 116. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 117. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 118. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 119. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 120. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 121. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 122. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 123. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 124. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 125. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 126. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 127. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 128. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 129. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 130. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 131. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 132. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 133. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 134. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 135. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 136. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 137. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 138. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 139. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 140. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 141. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 142. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 143. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 144. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 145. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 146. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 147. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 148. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 149. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 150. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 151. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 152. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 153. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 154. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 155. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 156. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 157. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 158. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 159. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 160. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 161. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 162. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 163. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 164. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 165. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 166. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 167. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 168. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 169. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 170. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 171. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 172. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 173. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 174. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 175. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 176. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 177. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 178. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 179. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 180. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 181. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 182. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 183. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 184. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 185. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 186. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 187. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 188. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 189. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 190. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 191. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 192. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 193. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 194. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 204. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 205. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 206. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 207. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 208. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 209. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 210. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 211. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 212. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 213. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 214. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 215. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 216. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 217. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 218. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 219. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 220. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 221. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 222. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 223. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 224. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 225. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 226. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 227. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 228. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 229. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 230. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 231. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 232. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 233. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 234. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 235. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 236. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 237. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 238. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 239. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 240. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 241. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 242. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 243. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 246. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 247. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 248. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 249. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 250. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 251. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 252. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 253. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 254. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 255. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 256. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 257. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 258. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 259. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 271. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 272. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 273. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 274. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 275. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 276. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 277. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 278. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 279. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 280. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 281. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 282. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 283. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 284. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 285. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 286. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 287. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 288. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 289. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 290. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 291. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 292. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 293. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 294. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 295. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 296. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 297. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 298. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 299. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 300. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 301. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 302. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 303. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 304. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 305. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 306. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 307. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 308. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 310. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 312. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 314. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 316. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 318. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 320. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 322. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 324. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
TABLE 325. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 326. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 327. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 328. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 329. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 330. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 331. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 332. SWEDEN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MI

Companies Mentioned

The leading players in the Lung Cancer Therapeutics Market, which are profiled in this report, include:

AbbVie Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Boehringer Ingelheim GmbH
Bristol Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
F. Hoffmann-La Roche AG
Genentech, Inc.
GlaxoSmithKline PLC
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi S.A.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	193
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 27.12 Billion
Forecasted Market Value ( USD ) by 2030	$ 44.03 Billion
Compound Annual Growth Rate	8.3%
Regions Covered	Global
No. of Companies Mentioned	14

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3542EUR$3,545USD£2,939GBP €3936EUR$3,939USD£3,266GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6267EUR$6,272USD£5,201GBP €6963EUR$6,969USD£5,778GBP

Understanding Market Dynamics in the Lung Cancer Therapeutics Market

Exploring Porter’s Five Forces for the Lung Cancer Therapeutics Market

Applying PESTLE Analysis to the Lung Cancer Therapeutics Market

Analyzing Market Share in the Lung Cancer Therapeutics Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Lung Cancer Therapeutics Market

Strategic Recommendations for Success in the Lung Cancer Therapeutics Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Lung Cancer Drugs Market by Disease, Molecule, Distribution Channel - Global Forecast 2025-2030

Lung Cancer Therapeutics - A Global Market Overview

Non-small Cell Lung Cancer Therapeutics Market by Cancer Type, Drug Class, Distribution Channel - Global Forecast 2025-2030

Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report By Type (Squamous Cell Carcinoma), By Treatment (Chemotherapy), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

Extensive Stage Small Cell Lung Cancer Market by Treatment Modalities, Drug Type, Route of Administration, Distribution Channel - Global Forecast 2025-2030